Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-099393
Filing Date
2026-03-10
Accepted
2026-03-10 07:48:55
Documents
59
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tennx-20251231.htm   iXBRL 10-K 2696187
2 EX-4.16 tennx-ex4_16.htm EX-4.16 40876
3 EX-23.1 tennx-ex23_1.htm EX-23.1 3739
4 EX-31.1 tennx-ex31_1.htm EX-31.1 15684
5 EX-31.2 tennx-ex31_2.htm EX-31.2 17853
6 EX-32.1 tennx-ex32_1.htm EX-32.1 9236
7 EX-32.2 tennx-ex32_2.htm EX-32.2 8623
  Complete submission text file 0001193125-26-099393.txt   8279077

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20251231.xsd EX-101.SCH 882295
61 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20251231_htm.xml XML 1345633
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34600 | Film No.: 26737252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)